GUFICBIONSEGufic Biosciences Limited· PharmaceuticalsMediumNeutral
Announced Fri, 29 May · 22:58 IST

Gufic Biosciences Limited has informed the Exchange regarding Change in Auditors of the company.

Management Changes View source PDF

GUFICBIO · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reaction · full curve 14 horizons · vs prior close
+6.2%1-day move
₹332.15
prior close
₹342.00
base price
After-mkt
timing
5m10m15m30m1D2D3D4D5D7D15D1M2M3M
+0.2+0.2-1.7+2.0+6.2+9.0+6.0+12.1+13.5+9.3+7.8+18.9
Up moveDown movePending
AI summary

Gufic Biosciences' Board of Directors has approved two auditor appointments at its meeting on May 29, 2026. The company re-appointed M/s. Poddar & Co., Cost Accountants as Cost Auditors for Financial Year 2026-27. Additionally, Mrs. Saroj R. Kirdolia, a Chartered Accountant with 7+ years of experience including 6 years with the company, has been appointed as Internal Auditor for FY 2026-27. The Cost Auditor is a statutory requirement while the Internal Auditor will evaluate internal controls and business processes. Both appointments are routine governance matters with standard terms.

Likely market impact

These are routine auditor appointments and do not indicate any accounting concerns or governance issues. The re-appointment of an existing cost auditor and hiring of a familiar internal auditor suggests stable financial oversight. Shareholders should view this positively as it reflects normal operational governance.